IBIO Stock Overview
A preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
iBio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.64 |
| 52 Week High | US$6.12 |
| 52 Week Low | US$1.02 |
| Beta | -3.37 |
| 11 Month Change | -7.37% |
| 3 Month Change | 33.20% |
| 1 Year Change | -52.82% |
| 33 Year Change | -99.20% |
| 5 Year Change | -95.23% |
| Change since IPO | -99.94% |
Recent News & Updates
Shareholder Returns
| IBIO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 15.8% | 2.5% | 2.2% |
| 1Y | -52.8% | 16.1% | 31.6% |
Return vs Industry: IBIO underperformed the US Biotechs industry which returned 16.2% over the past year.
Return vs Market: IBIO underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| IBIO volatility | |
|---|---|
| IBIO Average Weekly Movement | 11.6% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: IBIO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: IBIO's weekly volatility has decreased from 31% to 12% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 16 | Martin Brenner | ibioinc.com |
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company’s technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and trophoblast cell surface antigen 2, a monoclonal antibodies, as well as MUC16 and Target 5 antibodies.
iBio, Inc. Fundamentals Summary
| IBIO fundamental statistics | |
|---|---|
| Market cap | US$24.15m |
| Earnings (TTM) | -US$14.36m |
| Revenue (TTM) | US$175.00k |
138.0x
P/S Ratio-1.7x
P/E RatioIs IBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IBIO income statement (TTM) | |
|---|---|
| Revenue | US$175.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$175.00k |
| Other Expenses | US$14.53m |
| Earnings | -US$14.36m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.57 |
| Gross Margin | 100.00% |
| Net Profit Margin | -8,204.57% |
| Debt/Equity Ratio | 5.3% |
How did IBIO perform over the long term?
See historical performance and comparison